@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix RNA: . @prefix hgnc: . @prefix geneProductOf: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:2674; a RNA: . sub:_2 occursIn: species:9606; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject chebi:46024; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:\"trichostatin A\") -> r(HGNC:DAPK1)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "20131211" . sub:_3 prov:value "(from text) Interestingly, treatment of MM cell lines with TSA alone also resulted in up-regulation of important cancer-related genes including ING1p33, TIMP3, CDKN2D, PTENP1, CDKN1C/p57KIP2, DAPK, and WIG1, suggesting that aberrant histone deacetylation is an important mechanism for inactivation of cancer-related genes in MM."; prov:wasQuotedFrom pubmed:18172295 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:18172295; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:14.414+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }